仙琚製藥(002332.SZ)業績快報:2020年淨利升23.15%至5.05億元
格隆匯2月24日丨仙琚製藥(002332.SZ)披露2020年度業績快報,報吿期內,公司實現營業收入40.15億元,同比增長8.27%;營業利潤6.29億元,同比增長15.69%;利潤總額6.38億元,同比增長21.07%;歸屬於上市公司股東的淨利潤5.05億元,同比增長23.15%;實現每股收益0.54元,同比增長20.00%。
報吿期內,公司營業收入、利潤總額、歸屬於上市公司股東的淨利潤同比保持增長,主要原因是2020年公司原料藥板塊國外市場訂單充裕,製劑板塊銷售逐季改善,意大利子公司Newchem公司克服疫情初期影響生產逐步恢復正常。公司聚焦甾體激素主業,緊盯市場需求,加快新產品開發和技術平台建設,持續夯實綜合基礎能力。
報吿期末,公司總資產67.91億元,同比增長16.59%;歸屬於上市公司股東的所有者權益43.57億元,同比增長48.13%。歸屬於上市公司股東的所有者權益增加的主要原因,系報吿期內非公開發行股票募集資金完成以及報吿期內經營業績增長所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.